# Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Study · id `cardio:ct-nct05001945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05001945](<https://clinicaltrials.gov/study/NCT05001945>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05001945

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT05001945. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2022-09-07 (actual). Results posted on 2024-01-05.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT05001945, source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)
- Started: 2021-07-01 (actual) (ClinicalTrials.gov record NCT05001945, source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)
- Primary completion: 2022-09-07 (actual) (ClinicalTrials.gov record NCT05001945, source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)
- Completion: 2022-10-07 (actual) (ClinicalTrials.gov record NCT05001945, source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)
- Results first posted: 2024-01-05 (ClinicalTrials.gov record NCT05001945, source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05001945, source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05001945-2024-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
- Acronym: Target-HTN
- Condition: Hypertension, Renal
- Intervention (Drug): MLS-101 (Part I)
- Intervention (Other): Placebo (Part I)
- Intervention (Other): Placebo (Part II)
- Intervention (Drug): MLS-101 (Part II)
- Lead sponsor: Mineralys Therapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Mineralys Therapeutics Inc. (`cardio:org-mineralys-therapeutics-inc`)

## Provenance

Content hash: 91e211e7fe6ab434994ae4b9d4177fe54434c310340c5ca4f9b8aa81db65da45
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
